Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 170

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis

Open access
Moreau, Richard, Elkrief, Laure, Bureau, Christophe, Perarnau, Jean-Marc, Thévenot, Thierry, Saliba, Faouzi, Louvet, Alexandre, Nahon, Pierre, Lannes, Adrien, Anty, Rodolphe, Hillaire, Sophie, Pasquet, Blandine, Ozenne, Violaine, Rudler, Marika, Ollivier-Hourmand, Isabelle, Robic, Marie Angèle, d'Alteroche, Louis, Di Martino, Vincent, Ripault, Marie-Pierre, Pauwels, Arnaud, Grangé, Jean-Didier, Carbonell, Nicolas, Bronowicki, Jean-Pierre, Payancé, Audrey, Rautou, Pierre-Emmanuel, Valla, Dominique, Gault, Nathalie, Lebrec, Didier · 2018 · Gastroenterology

Abstract

BACKGROUND & AIMS: There is debate over the effects of long-term oral fluoroquinolone therapy in patients with advanced cirrhosis. We performed a randomized controlled trial to evaluate the effects of long-term treatment with the fluoroquinolone norfloxacin on survival of patients with cirrhosis. METHODS: We performed a double-blind trial of 291 patients with Child-Pugh class C cirrhosis who had not received recent fluoroquinolone therapy. The study was performed at 18 clinical sites in France from April 2010 through November 2014. Patients were randomly assigned to groups given 400 mg norfloxacin (n = 144) or placebo (n = 147) once daily for 6 months. Patients were evaluated monthly for the first 6 months and at 9 months and 12 months thereafter. The primary outcome was 6-month mortality, estimated by the Kaplan-Meier method, censoring spontaneous bacterial peritonitis, liver transplantation, or loss during follow-up. RESULTS: The Kaplan-Meier estimate for 6-month mortality was 14.8% for patients receiving norfloxacin and 19.7% for patients receiving placebo (P = .21). In competing risk analysis that took liver transplantation into account, the cumulative incidence of death at 6 months was significantly lower in the norfloxacin group than in the placebo group (subdistribution hazard ratio, 0.59; 95% confidence interval, 0.35-0.99). The subdistribution hazard ratio for death at 6 months with norfloxacin vs placebo was 0.35 (95% confidence interval, 0.13-0.93) in patients with ascites fluid protein concentrations <15 g/L and 1.39 (95% confidence interval, 0.42-4.57) in patients with ascites fluid protein concentrations ≥15 g/L. Norfloxacin significantly decreased the incidence of any and Gram-negative bacterial infections without increasing infections caused by Clostridium difficile or multiresistant bacteria. CONCLUSIONS: In a randomized controlled trial of patients with advanced cirrhosis without recent fluoroquinolone therapy, norfloxacin did not reduce 6-month mortality, estimated by the Kaplan-Meier method. Norfloxacin, however, appears to increase survival of patients with low ascites fluid protein concentrations. ClinicalTrials.gov ID: NCT01037959.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2018.08.026

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 170

Metadata

Authors
Moreau, R., Elkrief, L., Bureau, C., Perarnau, J.-M., Thévenot, T., Saliba, F., Louvet, A., Nahon, P., Lannes, A., Anty, R., Hillaire, S., Pasquet, B., Ozenne, V., Rudler, M., Ollivier-Hourmand, I., Robic, M. A., d'Alteroche, L., Di Martino, V., Ripault, M.-P., Pauwels, A., Grangé, J.-D., Carbonell, N., Bronowicki, J.-P., Payancé, A., Rautou, P.-E., Valla, D., Gault, N., & Lebrec, D.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2018-12
Volume
155
Issue
6
Pages
1816-1827.e9
ISSN
0016-5085 (ISSN-L)
OpenAlex
W2888547358
Cited by
170
References
6
FWCI
10.13
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis. https://app.cochat.ai/papers/10.1053/j.gastro.2018.08.026
The paper
Moreau, R., Elkrief, L., Bureau, C., Perarnau, J.-M., Thévenot, T., Saliba, F., Louvet, A., Nahon, P., Lannes, A., Anty, R., Hillaire, S., Pasquet, B., Ozenne, V., Rudler, M., Ollivier-Hourmand, I., Robic, M. A., d'Alteroche, L., Di Martino, V., Ripault, M.-P., . . . Lebrec, D. (2018). Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis. Gastroenterology. https://doi.org/10.1053/j.gastro.2018.08.026

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.